Effect of sample heat inactivation on test levels of HIT-IgG (PF4-H) detected by the ACL AcuStar

Emmanuel J. Favaloro; Soma Mohammed; Dea Donikian; Mayuko Kondo; Sayed Hamdam; Naomi Hocker; Timothy Brighton

doi:10.1016/j.thromres.2021.01.004

Effect of sample heat inactivation on test levels of HIT-IgG _(PF4-H) detected by the ACL AcuStar

Emmanuel J. Favaloro, Soma Mohammed, Dea Donikian, Mayuko Kondo, Sayed Hamdam, Naomi Hocker, Timothy Brighton

Nursing, Paramedicine and Healthcare Sciences

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Abstract

Heparin induced thrombocytopenia (HIT) characterises a significant complication of heparin therapy, whilst heparin in turn reflects a common anticoagulant, especially in hospital settings. Some patients develop antibodies that cause platelet activation, thrombin generation, and subsequently thrombosis (arterial, venous and/or microvascular) and related morbidity (‘pathological HIT’). The ACL AcuStar represents an emerging technology in the haemostasis field, and HIT testing (HIT-IgG (PF4-H) assay) is available. We recently reported our experience with this assay, identifying this as an excellent screen for pathological HIT antibodies (i.e., high association with a gold-standard functional assay, namely serotonin release assay; SRA).

Original language	English
Pages (from-to)	12-15
Number of pages	4
Journal	Thrombosis Research
Volume	200
Early online date	17 Jan 2021
DOIs	https://doi.org/10.1016/j.thromres.2021.01.004
Publication status	Published - 01 Apr 2021

Access to Document

10.1016/j.thromres.2021.01.004

Cite this

@article{0f62cdfd108641d2aae45ea8d98f537f,

title = "Effect of sample heat inactivation on test levels of HIT-IgG (PF4-H) detected by the ACL AcuStar",

abstract = "Heparin induced thrombocytopenia (HIT) characterises a significant complication of heparin therapy, whilst heparin in turn reflects a common anticoagulant, especially in hospital settings. Some patients develop antibodies that cause platelet activation, thrombin generation, and subsequently thrombosis (arterial, venous and/or microvascular) and related morbidity ({\textquoteleft}pathological HIT{\textquoteright}). The ACL AcuStar represents an emerging technology in the haemostasis field, and HIT testing (HIT-IgG (PF4-H) assay) is available. We recently reported our experience with this assay, identifying this as an excellent screen for pathological HIT antibodies (i.e., high association with a gold-standard functional assay, namely serotonin release assay; SRA).",

keywords = "Heat inactivation, Heparin induced thrombocytopenia, HIT diagnosis, Laboratory testing",

author = "Favaloro, {Emmanuel J.} and Soma Mohammed and Dea Donikian and Mayuko Kondo and Sayed Hamdam and Naomi Hocker and Timothy Brighton",

year = "2021",

month = apr,

day = "1",

doi = "10.1016/j.thromres.2021.01.004",

language = "English",

volume = "200",

pages = "12--15",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier",

}

TY - JOUR

T1 - Effect of sample heat inactivation on test levels of HIT-IgG (PF4-H) detected by the ACL AcuStar

AU - Favaloro, Emmanuel J.

AU - Mohammed, Soma

AU - Donikian, Dea

AU - Kondo, Mayuko

AU - Hamdam, Sayed

AU - Hocker, Naomi

AU - Brighton, Timothy

PY - 2021/4/1

Y1 - 2021/4/1

N2 - Heparin induced thrombocytopenia (HIT) characterises a significant complication of heparin therapy, whilst heparin in turn reflects a common anticoagulant, especially in hospital settings. Some patients develop antibodies that cause platelet activation, thrombin generation, and subsequently thrombosis (arterial, venous and/or microvascular) and related morbidity (‘pathological HIT’). The ACL AcuStar represents an emerging technology in the haemostasis field, and HIT testing (HIT-IgG (PF4-H) assay) is available. We recently reported our experience with this assay, identifying this as an excellent screen for pathological HIT antibodies (i.e., high association with a gold-standard functional assay, namely serotonin release assay; SRA).

AB - Heparin induced thrombocytopenia (HIT) characterises a significant complication of heparin therapy, whilst heparin in turn reflects a common anticoagulant, especially in hospital settings. Some patients develop antibodies that cause platelet activation, thrombin generation, and subsequently thrombosis (arterial, venous and/or microvascular) and related morbidity (‘pathological HIT’). The ACL AcuStar represents an emerging technology in the haemostasis field, and HIT testing (HIT-IgG (PF4-H) assay) is available. We recently reported our experience with this assay, identifying this as an excellent screen for pathological HIT antibodies (i.e., high association with a gold-standard functional assay, namely serotonin release assay; SRA).

KW - Heat inactivation

KW - Heparin induced thrombocytopenia

KW - HIT diagnosis

KW - Laboratory testing

UR - http://www.scopus.com/inward/record.url?scp=85099932672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099932672&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2021.01.004

DO - 10.1016/j.thromres.2021.01.004

M3 - Letter

C2 - 33508737

AN - SCOPUS:85099932672

SN - 0049-3848

VL - 200

SP - 12

EP - 15

JO - Thrombosis Research

JF - Thrombosis Research

ER -

Effect of sample heat inactivation on test levels of HIT-IgG _(PF4-H) detected by the ACL AcuStar

Abstract

Access to Document

Other files and links

Fingerprint

Cite this